Home
Live Updates
Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC : comparemela.com
Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC
Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.
Related Keywords
Texas ,
United States ,
America ,
American ,
Bristol Myers Squibb ,
Tina Cascone ,
University Of Texas Md Anderson Cancer Center ,
Boehringer Ingelheim ,
Mark Foundation For Cancer Research ,
American Joint Committee On Cancer ,
Astrazeneca ,
Serono ,
Genentech ,
Parker Institute For Cancer Immunotherapy ,
Society For Immunotherapy Of Cancer ,
Arrowhead Pharmaceuticals ,
Ideology Health ,
Cancer Center ,
American Joint Committee ,
North America ,
Mark Foundation ,
Cancer Research ,
Dava Oncology ,
Parker Institute ,
Myers Squibb ,
comparemela.com © 2020. All Rights Reserved.